Woodward Diversified Capital LLC Has $1.57 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Woodward Diversified Capital LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,004 shares of the medical research company’s stock after selling 175 shares during the quarter. Amgen comprises approximately 1.2% of Woodward Diversified Capital LLC’s investment portfolio, making the stock its 14th largest holding. Woodward Diversified Capital LLC’s holdings in Amgen were worth $1,565,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the 3rd quarter valued at $29,000. Heck Capital Advisors LLC purchased a new position in Amgen during the 4th quarter worth $36,000. Livelsberger Financial Advisory bought a new stake in shares of Amgen in the 3rd quarter worth $56,000. Finally, Kennebec Savings Bank bought a new stake in shares of Amgen in the 3rd quarter worth $57,000. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Leerink Partners decreased their price target on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. UBS Group cut their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Finally, Bank of America raised their target price on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $313.23.

Amgen Stock Performance

NASDAQ:AMGN opened at $293.54 on Friday. The business’s fifty day moving average is $272.04 and its 200 day moving average is $303.51. The firm has a market cap of $157.79 billion, a price-to-earnings ratio of 37.59, a PEG ratio of 2.87 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Research analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.24%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.